Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients

Hippokratia

Volumn 13, Issue 4, 2009, Pages 237-241

  Sioulis, A ^a   Malindretos, P ^a   Makedou, A ^a   Makris, P ^a   Grekas, Dimitrios ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Coagulation factors; Endothelial dysfunction; Hemodialysis; Thrombotic episodes

Indexed keywords

BLOOD CLOTTING FACTOR; THROMBOMODULIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THROMBOSIS;

EID: 70350145588     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Editorial. Controlling the epidemic of cardiovascular renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998; 32: 853-906.
2. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stoke Incidence Collaboration. Stroke. 1997; 28: 491-499.
3. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia: Multifaceted defect partially corrected by dialysis. Am J Med. 1985; 79: 552-559. (Pubitemid 16191207)
4. Gordge MP, Neild GH. Platelet function in uremia. Platelets. 1991; 2: 115-123.
5. Rabiner SF. Uremic bleeding. In: Spaet TH, ed. Progress in Hemostasis and Thrombosis. New York: Grune & Stratton; 1972; p. 233-250.
6. Remuzzi G, Benigni A, Dodesini P, et al. Platelet function in patients on maintenance hemodialysis: Depressed or enhanced? Clin Nephrol. 1982; 17: 60-63.
7. Zicker MB. Biological aspects of heparin action: Heparin and platelet function. Fed Prod. 1977; 36: 47-49. (Pubitemid 8016516)
8. Lindsay RM, Moorthy AV, Koens F, Linton AL. Platelet function in dialyzed and non-dialyzed patients with chronic renal failure. Clin Nephrol. 1975; 4: 50-57.
9. Ruzzeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood. 1987; 70: 895-904.
10. Kazatchkine M, Sultan Y, Caen JP, Bariety J. Bleeding in renal failure: A possible cause. BMJ. 1976; 2: 612-615.
11. Nermann RP, Marshall LR, Hurst PE. Bleeding in renal failure: A possible cause. BMJ. 1977; 1: 1601-1602.
12. Remuzzi G, Livio M, Roncaglioni MC, Mecca G, Donati MB, de Gaetano G. Bleeding in renal failure: Is von Willebrand factor implicated? BMJ. 1977; 2: 359-361.
13. Warrel RP Jr, Hultin MB, Coller BS. Increased factor VIII/ von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med. 1979; 66: 226-228. (Pubitemid 9098789)
14. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980; 303: 1318-1322. (Pubitemid 11194456)
15. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. Deamino-8-D-arginine vassopressin shortens the bleeding time in uremia. N Engl J Med. 1983; 308: 8-12. (Pubitemid 13211265)
16. Turitto VT, Weiss HJ. Red blood cells: Their dual role in thrombus formation. Science. 1980; 207: 541-543.
17. Viganò G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis. 1991; 18: 44-49.
18. Del Greco F, Soper WS, Krumlovsky FA, et al. Thrombosis of vascular access for hemodialysis. In: Remuzzi G, Rossi EC, ed. Haemostasis and the kidney. London: Butterworths; 1989; p. 303-308.
19. Blann A, Tarbener D. A reliable cell marker of endothelial cell dysfunction: does it exist? Brit J Haematol. 1995; 90: 244-248.
20. Gaussem P, Levy C, Verny M, Angles-Cano E. Endothelial cell markers (vWF, t-PA and PAI-1) in the elderly. Thromb Haemost. 1994; 72: 164-165. (Pubitemid 24202317)
21. Venkateswara K, Smith EJ, Alexander JW, Fidler JP, Pemmaraju SR, Pollack VE. Thromboembolic disease in renal allograft recipients. What is its clinical significance? Arch Surg. 1976; 111: 1086-1092.
22. Himmelfarb J, Holbrook D, McMonagle E, Ault K. Increased reticulated platelets in dialysis patients. Kidney Int. 1997; 51: 834-839. (Pubitemid 27157970)
23. Deguchi N, Ohigashi T, Tazaki H, Handa M, Ikeda Y. Hemodialysis and platelet activation. Nephrol Dial Transplant 1991; 2: 40-42.
24. Matsuda T, Takemoto Y, Kishimoto T, Maekawa M, Akutsu T. Mechanistic aspects of cellular interactions with artificial dialyzer membrane surfaces. Biomat Art Cells Art Org. 1990; 18: 579-584.
25. Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design: Platelet activation and factor VIII-related von Willebrand factor during hemodialysis. Am J Med. 1987; 83: 411-418.
26. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res. 1991; 64: 81-90.
27. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis. 1994; 23: 828-835. (Pubitemid 24173566)
28. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron. 1993; 63: 273-278. (Pubitemid 23082067)
29. Reber G, Stoermann C, de Moerloose P, Ruedin P, Leski M. Hemostatic disturbances by two hollow-fiber hemodialysis membranes. Int J Artif Organs. 1992; 15: 269-276.
30. Malyszko J, Malyszko S J, Mysliwiec M. Endothelial cell injury markers in Chronic Renal Failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney & Blood Pressure Research. 2004; 27: 71-77. (Pubitemid 38594558)
31. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non- cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant. 2006; 21: 1558-1595.
32. Racki S, Zaputovic L, Mavric Z, Vujicic B, Dvornik S. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail. 2006; 28: 427-433. (Pubitemid 44049788)
33. Chawla S. L, Krishnan M. Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodialysis International. 2009; 13: 222-234.
34. Lopez-Aquirre Y, Paramo JA. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb Res. 1999; 94: 95-101.
35. Borawski J, Naumnik B, Pawlak K, Mysliwiec M. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant. 2001; 16: 1442-1447. (Pubitemid 32640601)
36. Borawski J, Naumnik B, Mysliwviec M. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost. 2002; 8: 359-367. (Pubitemid 36008760)
37. Malyszko J, Mysliwviec M. Effects of different heparins on thrombin-activatable fibrinolysis Inhibitor-TAFI in hemodialyzed patients. J Thromb Haemost. 2003; S1: abstract no P0800.
38. Inoue A, Wada H, Takagi M, et al. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb Hemost. 2000; 6: 100-103. (Pubitemid 30230633)
39. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BH. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes. 1995; 44: 80-84.